REG - Angle PLC - New commercial agreement with large pharma

AngleAnnouncement

03/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240503:nRSC0926Na&default-theme=true

RNS Number : 0926N  Angle PLC  03 May 2024

 For immediate release  3 May 2024

 

 

ANGLE plc ("the Company")

 

NEW COMMERCIAL AGREEMENT WITH LARGE PHARMA

 

ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection
assay for use in prostate cancer studies

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is delighted to announce that it has signed
a supplier agreement to develop a Parsortix-based Androgen Receptor(1) (AR)
detection assay for use in prostate cancer studies. The supplier agreement
reported here is with AstraZeneca (LSE/STO/Nasdaq: AZN). This follows an
earlier agreement to develop a methodology for CTC micronuclei detection using
the Company's DNA Damage Response (DDR) assay, announced on 24 April 2024.

 

Under the terms of this agreement, worth £550,000 to ANGLE, the Company will
develop a CTC-based AR assay. Assay development will take place in the ANGLE's
UK laboratories, with project completion expected in Q1 2025. A successful
development phase will demonstrate the importance of the Parsortix system in
assessing the efficacy of prostate cancer therapeutics and offers the
potential for long-term, ongoing business for the Company supporting clinical
studies.

 

AR is a nuclear protein involved in cell growth and proliferation, cell cycle
progression, protein synthesis, and cell death. The analysis of Parsortix(®)
harvested CTCs using the Company's AR assay could enable longitudinal,
minimally invasive assessment of AR status throughout clinical studies and
during follow-up.  There are more than 130 active, interventional oncology
clinical studies in 30,000 participants, which include androgen receptor
assessment, registered on clinicaltrials.gov.

 

 

ANGLE Chief Executive Officer, Andrew Newland, commented:

"This is further validation of ANGLE's Parsortix system which shows potential
for long-term large-scale revenues in bringing innovative new cancer drugs to
the market. We anticipate that success in this first phase of assay
development may lead to much larger contracts for use of the assay in clinical
trials."

 

ANGLE Chief Scientific Officer, Karen Miller commented:

"We are delighted our expertise is being put to use in the isolation, harvest,
and profiling of CTCs for androgen receptor investigation with the potential
for ANGLE's assays to be used in clinical trials. The new androgen receptor
assay will also be an important addition to the menu of assays we can offer
other customers."

 

 

1.   Prostate cancer is the second most common cancer in men with 1.5
million new cases diagnosed globally each year and 5 million men living with
prostate cancer (5-year prevalence). The androgen receptor plays a pivotal
role in prostate cancer tumour growth and progression with anti-androgen
therapy frequently given as first-line treatment. However, response is
variable, and 20-30% of patients go on to develop resistance, resulting in
disease progression and the development of metastatic castration resistant
prostate cancer (mCRPC), which is currently incurable.

 

 

 

 

For further information:

 

 ANGLE plc                                +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Corporate Broker)   +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin               +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                 +1 (212) 850 5624

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a
regulatory information service, this information is considered to be in the
public domain.

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumour cell (CTC) harvesting technology known as the Parsortix(®)
PC1 System enables complete downstream analysis of the sample including whole
cell imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system, associated
consumables and assays. The clinical services business is offered through
ANGLE's GCLP-compliant laboratories.  Services include custom made assay
development and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRUUAARSWUVRUR